<DOC>
	<DOC>NCT02059785</DOC>
	<brief_summary>This research is a Randomized, double-blind, placebo-controlled, multicenter clinical study. Chinese subjects with Ischemic Stroke.</brief_summary>
	<brief_title>Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke</brief_title>
	<detailed_description>Subjects will randomly enter into one of two groups,the period of treatment is 14 days,follow-up to the 90th days.</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>3575 hospitalized patients Patients with acute stroke ≤24h NIHSS score 620 at time of enrollment , the score ≥2 of item 5 and/or 6 For the first time or always without obvious sequelae of stroke disease(mRS≤1） Informed consent The disease such as Acute intracerebral hemorrhage,tumor and encephalitis which cause similar symptoms Patient with NIHSS level of consciousness score≥2 or dementia,or other patients who the investigator think that don't fit into the study TIA Symptoms of disease rapidly improving during the randomized Severe hypertension(SBP &gt; 200 mmHg or DBP &gt;110 mmHg) Inadequate liver function(AST or ALT greater than 2 times the upper limit of normal values);Renal impairment (Creatinine clearance ＜60ml/min） Severe system or viscera organic disease Have used other neuroprotectant or other experimental drugs Patient who are unlikely to complete the study that due to a severe clinical condition Pregnant or breastfeeding Participation in a previous clinical study within 30 days Meets all other exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pinocembrin for Injection</keyword>
	<keyword>Placebo</keyword>
	<keyword>mRS</keyword>
</DOC>